Background
In colorectal cancer, prognostic value of immune cell infiltrate in the tumor tissue have been reported 1−3) .
Intensity of the levels of immune cell invasion influenced
an outcome of not only immunotherapy but also chemotherapy and even surgery. These findings had made us believe that blockade of negative feedback pathways utilized by cancer cells to escape from host immunity, by means of anti-PD1 therapy for example, facilitate the immune cell infiltration leading to clinical benefits in colorectal cancer and many other types of cancer including melanoma, non-small cell lung cancer 4) , Hodgkin's lymphoma 5, 6) , head and neck squamous cell carcinoma 7) and bladder cancer 8) . However, in colorectal cancer, unlike other types of cancer, only the patients deficient of mismatch repair (MMR) gene showed response to PD-1 antibody administration 9) . MMR deficiency, which in turn bring microsatellite instability-high phenotype (MSI-H), was reported to be caused by Lynch syndrome, in which germline mutation of MMR on one allele followed by somatic inactivation of second allele, or sporadic cases which result from epigenomic silencing mainly following to BRAF mutation in serrated polyp 10, 11) . It has been reported that pre-existing anti-tumor immune reactions greatly affects the sensitivity to anti-PD1 therapy 12) . Therefore, since MSI-H colon cancer harbor larger numbers of immunogenic mutations and neo-antigens 2, 13) , high responsiveness to immune checkpoint inhibitors could be plausible 9) . However, statistical analysis of summary Efficacy of immune checkpoint inhibitors such as PD-1 antibody for colorectal cancer remains to be proved except in microsatellite-instability-high (MSI-H) cases. While the objective response rate of MSI-H cases was 40%, that of microsatellite-stable (MSS) cases was 0%, showing that response rate to immune checkpoint inhibitors varies even among the microsatellite status. Some possible mechanisms that confer each patient variation in the response to immunotherapy should be considered. We focused on the combination of inter-patient heterogeneity and intra-tumor heterogeneity as a determining factor of immune reaction. An example of intra-tumor heterogeneity is the low expression of tumor antigen by CD271
+ cells in melanoma. It is not surprising that similar mechanism exists in CRC. Other related intra-tumor heterogeneity includes EMT and autophagy, both molecular mechanisms that are thought to promote immune-evading phenotype. Besides the microsatellite status, inter-patient heterogeneity in response to tumor immunity includes hypermutator phenotype, which is driven by POLE mutation, intrinsic cytokine production, and microbiota in the gut.
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Inter-patient heterogeneity and intra-tumor heterogeneity involved in immune reaction against colorectal cancer.
In this review, we focus on the tumor heterogeneity involved in tumor-targeted immune reaction. Genetic and phenotypic variations are observed among individuals with the same tumor type (inter-patients heterogeneity).
Within a tumor, there is subclonal diversity of tumor cells (intra-tumor heterogeneity) 14) . Inter-patient heterogeneity in tumor immunity result from genetic background involved in carcinogenesis, such as mismatch repair gene deficiency and POLE mutation, and personal disease-modifying factors, such as composition of intestinal bacterial flora 15, 16) , smoking status and pre-existing disease. These factors of inter-patient heterogeneity were previously evaluated by analyzing therapeutic response data, clustering analysis preceded by DNA microarray analysis, and whole exome sequencing which revealed DNA mutation load found in each patient ( Table 1) . Tumor microenvironment of endometrial cancer with POLE mutation or MSI were immunologically active and characterized by the abundance of tumor specific neo-antigens and high levels of TILs infiltration 19−21) , leading to over-expression of PD-1 and PD-L1 19) in endometrial cancer. In colorectal cancer, Besides, recent studies demonstrated that a family of but not in colorectal cancer 24) , indicating that APOBEC in CRC remains controversial.
Inter-patient difference in chromosomal instability
and gene mutations which directly affect cytokine and chemokine production, and presentation of neo-antigens Bindia et al. reported that genomic instability of the CXCL13 was one mechanism, which determines the intensity of Tfh and B cell infiltration 25) . CXCL13 and One of the genes deleted was IL15 and its deletion corresponded with decreased IL15 expression, a higher risk of relapse, and worse prognosis 26) . These findings demonstrate chromosomal instability as a mechanism in tumor that changes its cytokine production.
E Tran et al. demonstrated the neo-antigen KRAS
G12D was recognized by HLA-C*08:02-restricted tumor-infiltrating lymphocytes that were composed of multiple clones, each of which specifically targeted KRAS G12D 27) . They also reported a case of HLA-C* 08:02 patients with 7 lung metastatic lesions of CRC treated by adopted immunotherapy using their KRAS G12D-directed HLA-C*08:02-restricted tumor-infiltrating lymphocytes. Although objective regression of all metastatic lesions was observed after the treatment, one of these lesions progressed 9 months after the therapy.
The lesion was resected and found to have lost the chromosome 6 haplotype encoding the HLA-C*08:02 class I MHC. These findings showed inter-tumor heterogeneity formed by the loss of molecules needed for antigen pre-
. . Phenotypic heterogeneity defined by surface antigens were reported in many types of cancer such as melanoma 30) , but it has been controversial that whether a particular subpopulation harboring such immunological phenotypes affect the sensitivity to tumor-targeted immunity. Some CD antigens were reported for defining a particular characteristic subpopulation ( Table 2) . However, their properties were mainly elucidated not from the tumor-mesenchymal interaction but their genetic back- , LGR5 + 32) , and CD44v6 + 33) . via production of CCL2 and subsequent induction of immunoregulatory dendritic cells (regDC) 38) . . 
Intra

Conclusion
